/ Keyword (s): Quarterly Results / Quarterly / Interim Declaration

05/31/2021 / 08:37

The issuer is solely responsible for the content of this announcement.

HAEMATO AG with a strong start to the year: EBIT increases in the first quarter by 350% to EUR 2.4 million and sales by 22% to EUR 73.9 million .
Berlin, May 31st, 2021 – HAEMATO AG (ISIN: DE000289VV1) continued on its growth path in the first months of 2021. Due to a strong core business, consolidated sales (IFRS) rose by 22% to EUR 73.9 million in the first quarter. The specialist in drugs for the treatment of chronic diseases and for individual therapies increased income at all levels disproportionately. The result from ordinary activities (EBITDA) rose by 196% to EUR 2,823 thousand (previous year: EUR 954 thousand) and the operating result (EBIT) by 350% to EUR 2,428 thousand. This means that the EBIT after the first three months of the current year is already above the total value for 2020. One reason for the increase in earnings is the improvement in the gross margin, which rose from 7.2% (previous year) to 9.8% in the first quarter of 2021 .

“HAEMATO has streamlined its product portfolio in recent years and has consistently concentrated on high-margin areas with sustainable growth potential. This is increasingly paying off,” says Patrick Brenske, CEO of HAEMATO. “Our growth drivers today are special drugs against chronic diseases and products related to aesthetic medicine. The demand for medical cannabis clearly exceeds our supply and we are currently looking for additional suppliers.”

At the end of March 2021, the subsidiary HAEMATO PHARM GmbH received from the federal institute for pharmaceuticals and medical devices (BfArM) a special permit for a Covid 19 antigen rapid test for self-testing by laypeople. As early as April and May 2021, medical products from the “Diagnostics” segment achieved a sales volume of almost EUR 25 million, which will have a positive impact on the business figures for the second quarter of 2021. Medium-term demand for Covid 19 rapid tests largely depends on the further course of the pandemic, the vaccination rate and the national test strategy in Germany.

Due to the ongoing corona pandemic, HAEMATO AG will again make use of the opportunity to offer shareholders a shortened A notice period of 21 days for the company’s general meeting on July 13, 2021.

HAEMATO AG, founded in 1993, is a pharmaceutical company. The focus of its business activities is on the trade in high-priced specialty drugs (with a therapeutic focus on cancer, HIV and other chronic diseases) as well as on the development and sale of medical products and private labels, especially in the field of “aesthetic medicine”. HAEMATO AG is listed on the Basic Board (Open Market) of the Frankfurt Stock Exchange. More information at: www.haemato.ag.

May 31, 2021 Distribution of company news transmitted by DGAP – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. DGAP sales services include government announcements, financial / corporate news, and press releases. Archive at www.dgap.de

PharmiWeb.com is Europe’s leading industry sponsored portal for the pharmaceutical sector, providing the latest job vacancies, news, features and listings of events. The information provided on PharmiWeb.com is intended to support the relationship between a patient / patient and not to replace the site visitor and his / her doctor.

This website is protected by reCAPTCHA and the Google Privacy Policy and Terms of Use apply.

follow us

Copyright © 2021 PHARMIWEB.COM LIMITED, rights reserved by their respective owners.

Disclaimer: You are leaving the PharmiWeb.com website and are visiting a website that is not operated by us. We are not responsible for the content or availability of linked pages.

PharmiWeb.com provides links to other third party websites that may be of interest to visitors to our website. The links provided on our website are for your convenience only and may help you find other useful information on the Internet. If you click on these links you will leave the PharmiWeb.com website and be redirected to another website. These websites are not under the control of PharmiWeb.com.

PharmiWeb.com is not responsible for the content of linked third party websites. We are not a representative of these third parties, nor do we endorse or guarantee their products. We do not give any representation or guarantee with regard to the correctness of the information contained on the linked pages. We recommend that you always check the information received from linked websites before reacting to this information.

Please also note that the security and privacy guidelines on these websites may differ from the guidelines of PharmiWeb.com. Therefore, read the privacy and security policies of third party providers carefully.

If you have any questions or concerns about the products and services offered on linked third party websites, please contact the third party directly.

Related title :
AKASOL Reports strong first quarter: sales tripled to EUR 24 million and positive EBITDA achieved
PRESS RELEASE: HAEMATO AG with a strong start to the year: EBIT increases in the first quarter by 350% to 2.4 million EUR and …
HAEMATO AG with a strong start to the year: EBIT rises by 350% in the first quarter to EUR 2.4 million and sales by 22% to

Ref: https://www.pharmiweb.com